GE HealthCare Reports 3% Sales Growth, Net Income Up 51%, Adjusted EPS Rises to $1.01

Reuters
30 Apr
GE HealthCare Reports 3% Sales Growth, Net Income Up 51%, Adjusted EPS Rises to $1.01

GE HealthCare Technologies Inc. reported a 3% increase in revenues, reaching $4.8 billion for the first quarter of 2025, with organic revenue growth at 4%. The company's net income attributable to GE HealthCare rose to $564 million, up from $374 million in the previous year, resulting in a net income margin of 11.8%, compared to 8.0% from the prior year. Adjusted earnings before interest and taxes $(EBIT)$ was reported at $715 million, an increase from $681 million, with an adjusted EBIT margin of 15.0%, up from 14.7%. Diluted earnings per share $(EPS)$ improved to $1.23 from $0.81 the previous year, while adjusted EPS increased to $1.01 from $0.90. The company noted strong order growth, with organic orders increasing by a record 10% year-over-year, and a total company book-to-bill ratio of 1.09 times. GE HealthCare's cash flow from operating activities was $250 million, down from $419 million, with free cash flow at $98 million compared to $274 million the previous year. Additionally, the Board of Directors authorized a $1 billion share repurchase program as part of the company's strategic financial initiatives.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GE HealthCare Technologies Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250430848589) on April 30, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10